Drug Discovery Chemistry

Total Page:16

File Type:pdf, Size:1020Kb

Drug Discovery Chemistry Save up to $200! Final Agenda Register by February 23 COVER CHI’s 13th Annual CONFERENCE AT-A-GLANCE PLENARY KEYNOTES SHORT COURSES Drug Discovery AGENDA Plenary April 3-4 Conferences »» Protein-Protein Interactions Keynotes »» Inflammation»&»Autoimmune» Inhibitors Chemistry »» Kinase»Inhibitor»Chemistry Optimizing Small Molecules for Tomorrow's Therapeutics »» GPCR-Targeted Drug Design »» Fragment-Based»Drug» Activity-Based April 2-6, 2018 | San Diego, CA | Hilton San Diego Bayfront Discovery Proteomics: April 4-5 Conferences Protein and »» Ubiquitin»Proteasome»System» Ligand Discovery Inhibitors on a Global Scale CONFERENCE PROGRAMS »» Small»Molecules»for»Cancer» Benjamin F. Cravatt, Immunotherapy PhD, Professor and APRIL 3-4 APRIL 4-5 APRIL 6 Co-Chair, Department »» Macrocyclics»&»Constrained» of Molecular Peptides Medicine, The Protein-Protein Ubiquitin Proteasome Biophysical Approaches »» Targeting»Complex» Scripps Research Membrane»Proteins Institute Interactions System Inhibitors for Drug Discovery April 6 Symposia »» Biophysical»Approaches»for» Lead Optimization Inflammation & Small Molecules for Drug»Discovery for Drug Metabolism Autoimmune Inhibitors Cancer Immunotherapy »» Lead»Optimization»for»Drug» & Safety Metabolism»&»Safety » Targeting Ras » Blood-Brain»Penetrant» Kinase Inhibitor Macrocyclics & Blood-Brain Inhibitors and MYC for the Treatment of Chemistry Constrained Peptides Penetrant Inhibitors HOTEL & TRAVEL Cancer Stephen Fesik, SPONSORSHIP PhD, Professor GCPR-Targeted Targeting Complex Plus Short Courses & EXHIBIT of Biochemistry, Drug Design Membrane Proteins on April 2 & April 4 Pharmacology, and REGISTRATION Chemistry, Orrin H. Ingram II Chair in Cancer Research, Fragment-Based Click Here to register Online Vanderbilt University Drug Discovery DrugDiscoveryChemistry.com School of Medicine DrugDiscoveryChemistry.com Premier Sponsors: A Division of Cambridge Innovation Institute Save up to $200! Register by February 23 COVER CONFERENCE AT-A-GLANCE CONFERENCE AT-A-GLANCE PLENARY KEYNOTES SHORT COURSES AGENDA Monday Tuesday Wednesday Thursday Friday April 3-4 Conferences APRIL 2 APRIL 3 APRIL 4 APRIL 5 APRIL 6 »» Protein-Protein Interactions »» Inflammation»&»Autoimmune» Inhibitors BIOPHYSICAL PRE-CONFERENCE PROTEIN-PROTEIN COURSES* DINNER SHORT UBIQUITIN PROTEASOME » APPROACHES FOR » Kinase»Inhibitor»Chemistry SHORT COURSES* INTERACTIONS SYSTEM INHIBITORS »» GPCR-Targeted Drug Design DRUG DISCOVERY »» Fragment-Based»Drug» Discovery LEAD OPTIMIZATION INFLAMMATION & SMALL MOLECULES FOR April 4-5 Conferences FOR DRUG AUTOIMMUNE INHIBITORS CANCER IMMUNOTHERAPY »» Ubiquitin»Proteasome»System» METABOLISM & SAFETY Inhibitors »» Small»Molecules»for»Cancer» Immunotherapy KINASE INHIBITOR MACROCYCLICS & BLOOD-BRAIN »» Macrocyclics»&»Constrained» CHEMISTRY CONSTRAINED PEPTIDES PENETRANT INHIBITORS Peptides »» Targeting»Complex» Membrane»Proteins *Separate registration is required April 6 Symposia GCPR-TARGETED TARGETING COMPLEX »» Biophysical»Approaches»for» DRUG DESIGN MEMBRANE PROTEINS Drug»Discovery »» Lead»Optimization»for»Drug» Metabolism»&»Safety »» Blood-Brain»Penetrant» FRAGMENT-BASED Inhibitors DRUG DISCOVERY TRACK-HOPPING Attendees at Drug Discovery Chemistry are HOTEL & TRAVEL encouraged to “track-hop” between concurrent : Though you register for a particular SPONSORSHIP sessions conference or symposium, in reality you gain access to all & EXHIBIT concurrent conferences or symposia. For the best value, REGISTRATION register for a Premium Package, and gain access to all 12 conferences/symposia, plus two short courses, over five days of programming that best fits your research needs. Click Here to register Online DrugDiscoveryChemistry.com A Division of Cambridge Innovation Institute DrugDiscoveryChemistry.com • 2 Save up to $200! Register by February 23 COVER SPONSORS CONFERENCE AT-A-GLANCE PLENARY KEYNOTES PREMIER SPONSORS: SHORT COURSES AGENDA April 3-4 Conferences »» Protein-Protein Interactions »» Inflammation»&»Autoimmune» Inhibitors »» Kinase»Inhibitor»Chemistry »» GPCR-Targeted Drug Design »» Fragment-Based»Drug» Discovery April 4-5 Conferences CORPORATE SPONSORS: »» Ubiquitin»Proteasome»System» Inhibitors »» Small»Molecules»for»Cancer» Immunotherapy »» Macrocyclics»&»Constrained» Peptides »» Targeting»Complex» Membrane»Proteins April 6 Symposia »» Biophysical»Approaches»for» Drug»Discovery »» Lead»Optimization»for»Drug» Metabolism»&»Safety »» Blood-Brain»Penetrant» Inhibitors HOTEL & TRAVEL SPONSORSHIP & EXHIBIT REGISTRATION CORPORATE SUPPORT SPONSORS: Click Here to register Online DrugDiscoveryChemistry.com A Division of Cambridge Innovation Institute DrugDiscoveryChemistry.com • 3 Save up to $200! Register by February 23 PLENARY KEYNOTES COVER CONFERENCE AT-A-GLANCE PLENARY KEYNOTES April 3, 2018 | 4:40 pm April 5, 2018 | 8:55 am SHORT COURSES Activity-Based Proteomics: Protein and Targeting Ras and MYC for AGENDA Ligand Discovery on a Global Scale the Treatment of Cancer April 3-4 Conferences Benjamin F. Cravatt, PhD Stephen Fesik, PhD »» Protein-Protein Interactions Professor and Co-Chair, Department of Molecular Medicine, The Scripps Professor of Biochemistry, Pharmacology, and Chemistry, Orrin H. Ingram II »» Inflammation»&»Autoimmune» Research Institute Chair in Cancer Research, Vanderbilt University School of Medicine Inhibitors »» Kinase»Inhibitor»Chemistry Dr. Cravatt is a Professor and Co-Chair of the Department of Dr. Fesik’s research focus is on cancer drug discovery using »» GPCR-Targeted Drug Design Molecular Medicine at The Scripps Research Institute. His fragment-based approaches and structure-based drug »» Fragment-Based»Drug» research group is interested in understanding the roles that design. Prior to joining Vanderbilt in May 2009, Dr. Fesik was Discovery enzymes play in physiological and pathological processes, the Divisional Vice President of Cancer Research at Abbott April 4-5 Conferences especially as pertains to the nervous system and cancer. Dr. (2000-2009) where he built a pipeline of compounds that »» Ubiquitin»Proteasome»System» Inhibitors Cravatt obtained his undergraduate education at Stanford are showing promising anti-cancer activities in early stage »» Small»Molecules»for»Cancer» University, receiving a BS in the Biological Sciences and a BA clinical trials. While at Abbott, he also developed a few new Immunotherapy in History. He then received a PhD from The Scripps Research NMR methods, determined the three-dimensional structures »» Macrocyclics»&»Constrained» Institute (TSRI) in 1996. Professor Cravatt joined the faculty at of several proteins and protein/ligand complexes, pioneered Peptides »» Targeting»Complex» TSRI in 1997. Dr. Cravatt is a co-founder and scientific advisor a method for drug discovery called SAR by NMR, and applied Membrane»Proteins of Activx Biosciences, Abide Therapeutics, and Vividion this method to identify and optimize ligands for binding to April 6 Symposia Therapeutics. His honors include a Searle Scholar Award, the many protein drug targets. His research has also involved the »» Biophysical»Approaches»for» Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, use of siRNA for target identification and target validation. Drug»Discovery the Protein Society Irving Sigal Young Investigator Award, Dr. Fesik has published more than 240 papers, trained »» Lead»Optimization»for»Drug» Metabolism»&»Safety the Tetrahedron Young Investigator Award in Bioorganic 38 postdoctoral fellows, has been a reviewer for several »» Blood-Brain»Penetrant» and Medicinal Chemistry, the ASBMB Merck Award, and government funding agencies and has served as a member Inhibitors memberships in the National Academy of Sciences and of the Editorial Boards of many peer-reviewed journals. He HOTEL & TRAVEL American Academy of Arts and Sciences. is currently a member of Aileron Therapeutics SAB and the Bruker Board of Directors. His three awards from Abbott SPONSORSHIP & EXHIBIT include Researcher of the Year Team Award (2008). He has also received the NIH Director's Pioneer Award (2010), and REGISTRATION honors from numerous academic societies, the most recent being the AACR Award for Outstanding Achievement in Click Here to register Online Chemistry in Cancer Research (2012). DrugDiscoveryChemistry.com A Division of Cambridge Innovation Institute DrugDiscoveryChemistry.com • 4 Save up to $200! Register by February 23 APRIL 2ND & 4TH * COVER Short Courses CONFERENCE AT-A-GLANCE Afternoon Short Courses SC4: Diversity-Oriented Platforms for SC7: Introduction to Targeted Covalent Inhibitors Ligand Discovery Instructor: Mark Schnute, PhD, Associate Research PLENARY KEYNOTES Monday, april 2, 2:00 - 5:00 pM Instructors: Sepideh Afshar, PhD, Principal Research Fellow, Biotherapeutics Chemistry & Immunoscience SHORT COURSES Scientist, Department of Protein Engineering, Eli Lilly Research, Pfizer Global R&D SC1: Ligand-Receptor Molecular Interactions and Company • Overview of covalent drugs, irreversible AGENDA and Drug Design Svetlana Belyanskaya, PhD, Encoded Library and reversible inhibitors including recent Instructor: Maricel Torrent, PhD, Senior Scientist, AbbVie Technologies, R&D Platform Technology & Science, clinical examples April 3-4 Conferences • Drug design principles generally applicable to all GSK Boston • Biochemical analysis of covalent inhibitors »» Protein-Protein Interactions medicinal chemistry programs Pros and cons of affinity based screening platforms in • Design considerations for targeted »» Inflammation»&»Autoimmune» • Interpretation
Recommended publications
  • Specialists in Small Molecule Drug Development
    Specialists in Small Molecule Drug Development Dr Stephen Parker, Chairman Dr Tim Mitchell, CEO & Co-Founder Dr John Reader, CSO & Co-Founder Final Results for the Year Ending 30 June 2019 October 2019 www.sareum.co.uk Disclaimer The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Order, or (iii) those persons to whom it can otherwise be distributed without contravention of article 21 of the Financial Services and Markets Act 2000 (“FISMA”) or to whom it can lawfully be distributed. This Presentation has been prepared by Sareum Holdings PLC (“Company”) and provided to you for information purposes only. This Presentation is not an invitation or inducement to engage in an investment activity for the purposes of FISMA. This Presentation has not been approved by an Authorised Person (as defined in s31 FISMA), as would be required for financial promotions under s21 FISMA and, for the avoidance of doubt, is not a financial promotion for the purposes of FISMA. If, contrary to the above, this Presentation is deemed to be a financial promotion for the purposes of FISMA, the Company relies on the exemptions set out in Articles 19, 43, 59 and 69 of the Order, which exempts companies admitted to trading on relevant markets making certain communications. Please note that any indication of past performance should not be relied upon as a guide to future performance.
    [Show full text]
  • Enabling Comprehensive Assessments of Drug–Drug Interaction Risks
    R&D Solutions for PHARMA & LIFE SCIENCES PHARMACOVIGILANCE Enabling Comprehensive Assessments of Drug–Drug Interaction Risks Summary Dr. Kevin Lustig, President and CEO of The Assay Depot, Inc., and Dr. Maria Thompson, Principal Consultant, look at the dynamics of drug metabolizing enzymes and transporters and how an understanding of this critical aspect of biology enables assessments of drug–drug interaction risks. In addition, they comment on PharmaPendium®, which includes the DMPK solution with its DDI Risk Calculator, as an important tool in making these assessments successfully. Thanks to its comprehensive data on METs, PharmaPendium offers a unique platform for modeling advanced drug interactions. Abstract Understanding the dynamics of drug metabolizing enzymes and transporters (METs) is critical to successful drug development. MET behavior can significantly impact drug safety. Many factors regulate enzymes and transporters, which in turn affect the pharmacokinetic properties of drugs and mediate drug interactions. Evaluation of drug interaction profiles required detailed in vitro and in vivo studies along with predictive modeling. Thanks to its comprehensive data on METs, PharmaPendium offers a unique platform for modeling advanced drug interactions. This MET data and the ability to predict drug–drug interactions (DDIs) are incredibly valuable for optimized research workflows and accelerated drug development. They enable intelligent, in silico drug design and provide scientists with comprehensive knowledge about drug metabolism, significantly reducing the need for costly and time-consuming lab work and animal models and informing critical decisions on clinical trial design. Introduction Every successful drug discovery and development effort needs to factor in drug efficacy and safety, both of which are intimately linked to drug metabolism.
    [Show full text]
  • July Updates: People and Places
    career news July Updates: People and Places Skills and knowledge transfer alpha-synuclein A53T knock-in model; and commented in a press release, The NC3Rs has awarded a total of £219,339 the continued development of a pre-clinical “The partnership enables Scientist.com this year to three researchers through the model to test LRRk2 kinase inhibitors as a users to easily access innovative rodent 2018 NC3Rs Skills and Knowledge Transfer treatment for PD. models generated with the latest funding competition, designed to promote CRISPR technology.” the post-development uptake of new 3Rs Easi editing approaches. Laura Scullion Hall from The University of Nebraska recently Understanding aging fat the University of Stirling will partner with licensed its Easi-CRISPR gene editing Kristy Townsend, a neurobiologist at the pharmaceutical company GSK to develop technology to Taconic Biosciences. The University of Maine in Orono, has received an online learning platform for research dog CRISPR variant, developed by Masato a three-year $750,000 grant from the handling and welfare. Jonathan Brown from Ohtsuka at the University of Tokyo and American Heart Association to study links the University of Exeter will use the award Channabasavaiah Gurumurthy at the between fat tissue and cardiovascular and to apply the TaiNI wireless EEG recording University of Nebraska, enables the site- metabolic diseases in aging mouse models. technology he developed with scientists at specific insertion of large sequences Recent work from her lab has revealed Eli Lilly through the NC3Rs CRACK IT of DNA, an improvement to previous evidence of “adipose neuropathy”—fat Challenge to dementia research in mice.
    [Show full text]
  • 2019 Analyst Day
    2019 Analyst Day March 12, 2019 NASDAQ: LGND 2 Safe Harbor Statement The following presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and it’s partners’ judgment as of the date of this presentation. Words such as “plans,” “believes,” “expects,” “projects,” “could,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, financial projections, expectations regarding research and development programs, potential uses of capital, including any potential dividend or share repurchase program, and the timing of the initiation or compilation of preclinical studies and clinical trials by Ligand and its partners. Actual events or results may differ from Ligand’s expectations due to risks and uncertainties inherit in Ligand’s business, including: Ligand has wide discretion on its use of capital and may choose not to engage in any share repurchases, declare any dividends or pursue acquisitions or internal develop programs; Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline;, drug development program benefits may not be realized; Ligand will achieve its guidance in 2019 or thereafter; third party research summarized herein may not be correct or complete; Kyprolis®, EVOMELA® and Zulresso™ may not perform as expected, Ligand relies on collaborative partners for milestone and royalty payments,
    [Show full text]
  • Understanding Key Determinants of Drug Activity
    CASE STUDY Dr. Kevin Lustig, President and CEO, The Assay Depot, Inc. Greater San Diego Area Understanding Key Determinants of Drug Activity SUMMARY This article highlights the increasing role that drug metabolism and transport proteins have in the drug approval process. CASE STUDY: The Assay Depot, Inc. The dynamics of drug metabolizing enzymes and transporters is critical to the development of personalized medicine strategies. Abstract / Summary The dynamics of drug metabolizing enzymes and transporters is critical to the develop- ment of personalized medicine strategies. A multitude of factors regulate enzymes and transporters, which in turn affect the pharmacokinetic properties of drugs and medi- ate drug interactions. Evaluation of drug interaction profiles is a critical step in drug development and necessitates detailed in vitro and in vivo studies along with predictive modeling. PharmaPendium® via its Metabolizing Enzymes and Transporters Module provides unprecedented depth of data on drug metabolizing enzymes and transporters and offers a unique platform for modeling advanced drug interactions. This Module will prove to be a valuable resource capable of improving workflows and accelerating devel- opment by enabling intelligent, in silico drug design. By providing scientists with all of the available knowledge about drug metabolism, we can significantly reduce the need for costly and time-consuming lab work and animal models. Requiring these only to answer the true unknowns where no one else has gone before. Introduction Every successful drug discovery and development effort needs to factor in drug efficacy Dr. Kevin Lustig, Author and safety, both of which are intimately linked to drug metabolism. Hence knowledge President & CEO, The Assay Depot Inc.
    [Show full text]
  • Form 8-K Ligand Pharmaceuticals
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2020 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation or organization) Identification No.) 3911 Sorrento Valley Boulevard, Suite 110 San Diego CA 92121 (Address of principal executive offices) (Zip Code) (858) 550-7500 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    [Show full text]
  • Strategic Outsourcing of Pharmaceutical R&D
    CHEMSITRY TODAY Vol 31(4) P. 14-17 / CROS/CMOS Strategic outsourcing of pharmaceutical R&D - Bringing pharma and drug discovery into the information age KEVIN LUSTIG Assay Depot, Inc Corresponding Author KEVIN LUSTIG: Assay Depot, Inc, email: [email protected] KEYWORDS: Outsourcing; innovation; lean; drug; research; discovery ABSTRACT: The centralized model of pharmaceutical development that was used successfully through most of the last century is no longer a good fit. Advances in modern molecular research have changed the playing field to such an extent that the old model is no longer viable. If drug companies can solve the problems of pre-clinical development and deliver a steady stream of new, high- quality compounds to the clinic, then the challenges currently facing pharma will become a thing of the past. The single most likely route to success is through the application of strategic outsourcing, which if done correctly, can dramatically reduce research costs while simultaneously improving research quality. Utilizing new online tools such as research exchanges, a “lean” pharmaceutical company can find and manage a large number of specialist scientific service providers and experts that can bring exactly the right skill set to bear at the right time in the project cycle. INTRODUCTION Few would argue that the Pharmaceutical Industry has been languishing in the doldrums now for well over a decade. Pharmaceutical companies are having to face three major issues involving drug approvals, development costs and patents expirations. Any of these alone would prove a tough nut to crack, but the fact that they are all converging at the same time is creating a perfect storm! • A paucity of new drug approvals: 2010 was one of the worst years on record, with the European Medicines Agency showing only 41 finalized applications, compared to 125 in 2009.
    [Show full text]
  • Marketplaces for Sharing Scientific Data and Outsourcing R&D Activities: the Case Study of the Pharmaceutical, Life Sciences and Bio-Medical Industries
    MARKETPLACES FOR SHARING SCIENTIFIC DATA AND OUTSOURCING R&D ACTIVITIES: THE CASE STUDY OF THE PHARMACEUTICAL, LIFE SCIENCES AND BIO-MEDICAL INDUSTRIES In the present document, we aim to review the main protagonist companies in the field of the outsourcing of biomedical R&D research and in the sharing of scientific data and contract- research consultancy services. This effort is part of a longer-term objective aimed at assessing the current state of the R&D outsourcing market via “marketplace” type of websites, in order to estimate the existing potential competition to the core areas of interest of the VIMMP project. Even though, under the current state of affairs, no direct competitors of VIMMP presently exist (within the restricted field of materials modelling coupled with marketplace and data/software sharing type of functionalities), marketplace websites active in other branches of science and technology can still provide invaluable insight in demonstrating how such R&D commercial operations can be implemented and exploited successfully and profitably. 1. General Introduction to R&D Outsourcing Services Advances in science, technology, and engineering impact our daily lives and fuel economic growth and prosperity. Investment in innovation and R&D drives these advances, and it is the hi-tech companies and their respective industries that dominate global R&D spending. Hardware/software, electronics, automotive, aerospace and defense, telecommunications, and pharmaceutical/biotech all feature as the highest R&D spending industries. The pharmaceutical/biotech industry has the highest levels of R&D outsourcing across hi-tech industries, with its outsourcing growth rate outstripping internal investments. Some large pharmaceutical companies suggest that 40% or more of their R&D spend will be outsourced in the near future, and that clinical operations functions will eventually be outsourced entirely.
    [Show full text]
  • Motility of Acta Protein-Coated Microspheres Driven by Actin Polymerization
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 4908–4913, April 1999 Biophysics Motility of ActA protein-coated microspheres driven by actin polymerization LISA A. CAMERON*, MATTHEW J. FOOTER†,ALEXANDER VAN OUDENAARDEN‡, AND JULIE A. THERIOT†§¶ *Department of Biological Sciences, Stanford University, Stanford, CA 94305-5020; †Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305-5307; ‡Department of Chemistry, Stanford University, Stanford, CA 94305-5080; and §Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305-5124 Communicated by James A. Spudich, Stanford University School of Medicine, Stanford, CA, March 1, 1999 (received for review January 12, 1999) ABSTRACT Actin polymerization is required for the gen- moving endosomes (J. Heuser, personal communication) and eration of motile force at the leading edge of both lamellipodia phospholipid vesicles (11). Although much is understood and filopodia and also at the surface of motile intracellular about the biochemical mechanisms of catalyzing actin filament bacterial pathogens such as Listeria monocytogenes. Local polymerization in several of these systems (12–14), relatively catalysis of actin filament polymerization is accomplished in little is known about how this local surface catalysis results in L. monocytogenes by the bacterial protein ActA. Polystyrene comet tail formation, force generation, and motility. It is beads coated with purified ActA protein can undergo direc- striking that a variety of biochemical mechanisms for cata- tional movement in an actin-rich cytoplasmic extract. Thus, lyzing local actin polymerization on the surface of a small the actin polymerization-based motility generated by ActA can object (bacterium, virus, or membrane vesicle) all result in the be used to move nonbiological cargo, as has been demon- same type of actin self-organization and movement.
    [Show full text]
  • Milner Symposium 2020
    THERAPEUTICS SYMPOSIUM 2020 GLOBAL THERAPEUTIC ALLIANCE OVERVIEW A SERIES OF ONLINE EVENTS STARTING ON JUNE 12TH ALLIANCE GLOBAL THERAPEUTIC ALLIANCE The Milner Therapeutics Institute encompasses both a research institute and a global outreach programme for collaboration. GLOBAL THERAPEUTIC ALLIANCE Research in the Milner Therapeutics Institute is funded by: Our outreach programme is through the Global Therapeutic Alliance, which aims to build a global research community working together across academia and industry, with Cambridge providing a hub of expertise. The Milner Therapeutics Consortium is central to this aim (p4), and the Alliance has been expanded with the Affiliated Company p8( ) and Affiliated Institutions scheme p37( ) to bring complementary expertise and resources to the community, and provide opportunity to extend collaborative links within and beyond Cambridge. The Affiliated Venture Partnersprogramme, operational since October 2017, provides mentoring and potential funding opportunities for the Milner Therapeutics Institute and its Global Therapeutic Alliance, and especially for our in-house company accelerator Start Codon. 3 CONSORTIUM ASTEX PHARMACEUTICALS MILNER THERAPEUTICS CONSORTIUM The Milner Therapeutics Astex is a leader in innovative drug discovery and Consortium is an academic- development, committed to the fight against cancer and industry partnership, active since diseases of the central nervous system. Astex is developing June 2015. This is underpinned a proprietary pipeline of novel therapies and has multiple
    [Show full text]
  • Collaborative Drug Discovery's 10 Anniversary Community Meeting
    Collaborative Drug Discovery’s 10th Anniversary Community Meeting April 4th, 2014 8am-6pm UCSF Mission Bay Conference Center 1675 Owens St. San Francisco, CA 94158 Please use this Twitter hashtag for the event: #CDDx14 Agenda 7:45 Registration - refreshments in Foyer and Exhibition room 8:15 Opening Remarks - with UCSF Host, Stephanie Robertson and CDD CEO, Barry Bunin Collaborative Workflow: Basic and Advanced Use Cases of CDD Vault 8:20 Charlie Weatherall (CDD) & Anna Spektor (CDD) 9:10 Morning Sessions - moderated by Sylvia Ernst (CDD) The Rockefeller University Compound Screening Library 9:15 J. Fraser Glickman (Rockefeller University) Recent Progress in De-Orphanization of Nuclear Receptors 9:40 Ruo Steensma (Orphagen Pharmaceuticals) 10:05 Morning Break - located in the Foyer and Exhibition room Large small molecules in a Small large molecule world 10:35 Leanna Staben (Genentech) Linking the Molecular Structure of Medicines to their Biological Effects 11:00 Bob Volkmann (Systamedic & Mnemosyne Pharmaceuticals) Panel: Externalized Research - What Makes a Good Partnership? Wisdom from Experts 11:25 Who've "Been There - Done That," moderated by Sylvia Ernst (CDD) 11:50 Lunch - boxed lunches in the Foyer and Exhibition room Optional: “What if CDD had...” provide feedback to our product team (12:35) Kellan Gregory (CDD) 10 Years Evolving Our Collaborative Drug Discovery Vaults 1:05 Barry Bunin (CDD) CDD Vault: Noteworthy recent enhancements and a preview of things to come 1:30 David Blondeau (CDD) & Kellan Gregory (CDD) 2:20 Afternoon sessions - moderated Christopher Lipinski The Tuberculosis Drug Accelerator: A New Paradigm For Drug Discovery 2:25 Jerry Shipps (Tuberculosis Drug Accelerator) The role of NIAID in the development of therapeutics for Infectious Diseases 2:50 Martin John Rogers (NIAID) 3:15 Afternoon Break - located in the Foyer and Exhibition Room Targeting the Immunoproteasome 3:40 Dustin L.
    [Show full text]
  • 4586728.98 in 2005
    Detail Awards by Sponsor Dept Name FY05 Award Federal National Cancer Institute 47,048,096.55 National Institute of Heart, Lung, and Blood 38,794,591.33 National Institute of General Medicine Science 30,400,147.18 National Institute of Child Health & Human Development 29,863,697.92 National Institute of Allergy & Infectious Diseases 27,492,973.12 National Science Foundation - Research 20,659,748.00 National Institute of Diabetes, Digestive & Kidney Diseases 19,575,845.00 National Center for Research Resources 19,179,710.00 National Institute of Mental Health-NIH 16,727,938.80 US Department of Education 15,868,100.00 US Agency for International Development 12,743,904.00 National Institute of Environmental Health Sciences 11,961,787.00 National Institute of Neurologic Disorders and Stroke 11,957,697.00 Centers for Disease Control 10,507,132.00 National Institute of Dental and Craniofacial Research 7,032,009.35 National Institute on Alcohol Abuse & Alcoholism 6,874,910.00 Bureau of Health Professions 5,797,479.00 National Institute of Arthritis Musculoskeletal Skin Disease 4,921,205.00 US Environmental Protection Agency - GRANTS 4,586,728.98 National Institute on Aging 4,159,889.94 National Institute on Drug Abuse 4,111,248.00 National Institute of Nursing Research 4,094,244.00 National Institute of Biomedical Imaging and Bioengineering 4,079,842.59 Maternal and Child Health Bureau 4,049,730.00 National Science Foundation - Training 3,877,378.00 National Center for Chronic Disease Prev & Health Promo(CDC) 3,384,180.00 US Department of Defense
    [Show full text]